Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Mars CEO even joined the board of a top GLP-1 drug company
RB: Project administration, Writing review & editing
"On the basis of the current evidence the benefits of GLP-1 RAs outweigh the potential risks when used for the licensed indications." Mounjaro manufacturer Lilly said patient safety was the company's top priority
Documented weight loss results from the SURMOUNT-1 trial showed average losses of 34.4 pounds at the 5mg dose, 49 pounds at the 10mg dose, and 52 pounds at the 15mg dose over 72 weeks
Beyond the survey data discussed above, individual case reports and patient communities describe a range of experiences
At week 40, mean dose of insulin glargine was 38, 36, 29, and 59 units/day for patients receiving MOUNJARO 5 mg, 10 mg, 15 mg, and placebo, respectively
US$ 22.71
US$ 21.76
US$ 24.24
US$ 28.83
